

WE CLAIM:

1. A polypeptide comprising the amino acid sequence:

5 H-X2-X3-X4-G-T-F-T-S-D-V-S-S-Y-L-X16-G-Q-A-A-X21-E-F-X24-A-W-L-V-
R-G-R-G-X33-X34

wherein X2 is Ser, Ser(OMe), D-Ser, D-Ser(OMe), Ala or Aib, ;

X3 is absent or Gln;

X4 is Glu;


10 X16 is Glu;

X24 is Ile;

X33 is Leu, -D-Leu, D-Ile or Ile;

X34 is absent and

15 X21 is Lys wherein the side chain amino (ϵ amino) group of Lys is acylated with a moiety:




wherein Q and T are absent;

U is absent or $-C(O)-CH_2-O-(CH_2)_2-O-(CH_2)_2-NH-\}$ wherein $\}$ is point of attachment with group W;

20

W is absent or selected from a group consisting of $-C(O)-CH_2-O-(CH_2)_2-O-(CH_2)_2-NH-$, $-C(O)-NH-(CH_2)_{3-4}-NH-$, $-C(O)-C(CH_3)_2-NH-$ and



wherein $]$ is point of attachment with group Y;

Y is $-C(O)-(CH_2)_2-CH(COOH)NH--$ and $--$ is point of attachment with the group Z;

25

Z is $-C(O)-(CH_2)_n-COOH$ or $-C(O)-(CH_2)_n-CH_3$ wherein n is an integer from 14 to 20.

2. The polypeptide as in claim 1, wherein X2 is Aib;

30 X3 is absent;

X33 is Leu;

U is $-C(O)-CH_2-O-(CH_2)_2-O-(CH_2)_2-NH-\}$;


W is $-\text{C}(\text{O})-\text{CH}_2-\text{O}-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-\text{NH}-]$ and
 Z is $-\text{C}(\text{O})-(\text{CH}_2)_n-\text{COOH}$ wherein n is integer 16.

3. The polypeptide as in claim 1, wherein X2 is Aib;
 5 X3 is absent;
 X33 is Leu;
 U is $-\text{C}(\text{O})-\text{CH}_2-\text{O}-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-\text{NH}-\}$;
 W is $-\text{C}(\text{O})-\text{C}(\text{CH}_3)_2-\text{NH}-]$ and
 Z is $-\text{C}(\text{O})-(\text{CH}_2)_n-\text{COOH}$ wherein n is integer 16.

10

4. The polypeptide as in claim 1, wherein X2 is Aib;
 X3 is absent;
 X33 is Leu;
 U is $-\text{C}(\text{O})-\text{CH}_2-\text{O}-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-\text{NH}-\}$;
 15 W is $-\text{C}(\text{O})-\text{NH}-(\text{CH}_2)_4-\text{NH}-]$ and
 Z is $-\text{C}(\text{O})-(\text{CH}_2)_n-\text{COOH}$ wherein n is integer 16.

5. The polypeptide as in claim 1, wherein X2 is Aib;
 X3 is absent;
 20 X33 is Leu;
 U is $-\text{C}(\text{O})-\text{CH}_2-\text{O}-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-\text{NH}-\}$;
 W is



and

Z is $-\text{C}(\text{O})-(\text{CH}_2)_n-\text{COOH}$ wherein n is integer 16.

25

6. The polypeptide as in claim 1, wherein X2 is Aib;
 X3 is absent;
 X33 is Leu;
 U is $-\text{C}(\text{O})-\text{CH}_2-\text{O}-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-\text{NH}-\}$;
 30 W is $-\text{C}(\text{O})-\text{NH}-(\text{CH}_2)_3-\text{NH}-]$ and
 Z is $-\text{C}(\text{O})-(\text{CH}_2)_n-\text{COOH}$ wherein n is integer 16.

7. The polypeptide as in claim 1, wherein X2 is Ser, Ser(OMe), D-Ser, D-Ser(OMe);

X3 is absent;


X33 is Leu;

U is $-\text{C}(\text{O})-\text{CH}_2-\text{O}-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-\text{NH}-$;

W is $-\text{C}(\text{O})-\text{CH}_2-\text{O}-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-\text{NH}-$], $-\text{C}(\text{O})-\text{NH}-(\text{CH}_2)_{3-4}-\text{NH}-$], $-\text{C}(\text{O})-\text{C}(\text{CH}_3)_2-\text{NH}-$] and

Z is $-\text{C}(\text{O})-(\text{CH}_2)_n-\text{COOH}$ or $-\text{C}(\text{O})-(\text{CH}_2)_n-\text{CH}_3$ wherein n is an integer from 14 to 20.

8. The polypeptide as in claim 1, wherein W is selected from a group consisting of $-\text{C}(\text{O})-\text{NH}-(\text{CH}_2)_{3-4}-\text{NH}-$], $-\text{C}(\text{O})-\text{C}(\text{CH}_3)_2-\text{NH}-$] and



9. The polypeptide as in claim 1, wherein X2 is Ala;

X3 is absent;

X33 is Leu;

W is absent;

Z is $-\text{C}(\text{O})-(\text{CH}_2)_n-\text{CH}_3$ wherein n is integer 14.

10. The polypeptide as in claim 1, wherein X2 is Aib;

X3 is absent;

X33 is Leu;

W is absent;

Z is $-\text{C}(\text{O})-(\text{CH}_2)_n-\text{CH}_3$ wherein n is integer 14.